In line with our hypothesis that MB activated T‐cell function through inhibiting PD‐1 signaling, we found that PD‐1KO OT‐1 CTL on its own shrank tumor allografts and that MB treatment did not further significantly shrink the tumor volume (Fig EV4D, Appendix Fig S4F). Here, PDCD1 is linked to neoplasm.